 | • レポートコード：MRC2301A192 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、237ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥692,860 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,392,860 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の当調査資料では、2021年4,819.9億ドルであった世界のバイオ医薬品市場規模が、2022年には5,257.0億ドルになり、その後CAGR 9.32％で拡大して2027年までに8,229.1億ドルに達すると予想しています。当書は、バイオ医薬品の世界市場を総合的に分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品タイプ別（モノクローナル抗体、精製タンパク質、組換え増殖因子、組換えホルモン、組換えタンパク質）分析、サービス別（公定＆複数公定研究室試験、カスタム試験/顧客独自試験、実験室試験）分析、原材料別（医薬品有効成分（API）、公定法、製剤賦形剤）分析、用途別（自己免疫疾患、心血管疾患、ホルモン障害、炎症＆感染症、代謝障害）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報など、以下の構成でまとめています。なお、当書に掲載されている企業情報には、Abbott Laboratories、Abbvie Inc.、Amgen, Inc.、Biogen, Inc.、Bristol-Myers Squibb Company、Eli Lilly and Company、F. Hoffmann-La Roche, Ltd.、Johnson & Johnson、Merck & Co., Inc.、Novo Nordisk A/S、Pfizer, Inc.、Sanofi S.A.などが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のバイオ医薬品市場規模：製品タイプ別 - モノクローナル抗体の市場規模 - 精製タンパク質の市場規模 - 組換え増殖因子の市場規模 - 組換えホルモンの市場規模 - 組換えタンパク質の市場規模 ・世界のバイオ医薬品市場規模：サービス別 - 公定＆複数公定研究室試験の市場規模 - カスタム試験/顧客独自試験の市場規模 - 実験室試験の市場規模 ・世界のバイオ医薬品市場規模：原材料別 - 医薬品有効成分（API）の市場規模 - 公定法の市場規模 - 製剤賦形剤の市場規模 ・世界のバイオ医薬品市場規模：用途別 - 自己免疫疾患における市場規模 - 心血管疾患における市場規模 - ホルモン障害における市場規模 - 炎症＆感染症における市場規模 - 代謝障害における市場規模 ・世界のバイオ医薬品市場規模：地域別 - 南北アメリカのバイオ医薬品市場規模 アメリカのバイオ医薬品市場規模 カナダのバイオ医薬品市場規模 ブラジルのバイオ医薬品市場規模 ... - アジア太平洋のバイオ医薬品市場規模 日本のバイオ医薬品市場規模 中国のバイオ医薬品市場規模 インドのバイオ医薬品市場規模 韓国のバイオ医薬品市場規模 台湾のバイオ医薬品市場規模 ... - ヨーロッパ/中東/アフリカのバイオ医薬品市場規模 イギリスのバイオ医薬品市場規模 ドイツのバイオ医薬品市場規模 フランスのバイオ医薬品市場規模 ロシアのバイオ医薬品市場規模 ... - その他地域のバイオ医薬品市場規模 ・競争状況 ・企業情報 |
The Global Biopharmaceuticals Market size was estimated at USD 481.99 billion in 2021 and expected to reach USD 525.70 billion in 2022, and is projected to grow at a CAGR 9.32% to reach USD 822.91 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Biopharmaceuticals to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Product Type, the market was studied across Monoclonal Antibodies, Purified Proteins, Recombinant Growth Factors, Recombinant Hormone, Recombinant Proteins, Synthetic Immunomodulators, and Vaccines.
Based on Service, the market was studied across Compendial & Multi Compendial Laboratory Testing, Custom Testing / Customer Proprietary Testing, and Laboratory Testing.
Based on Raw Material Type, the market was studied across Active Pharmaceutical Ingredients (API), Compendial Methods, and ormulation Excipients.
Based on Application, the market was studied across Autoimmune Disorders, Cardiovascular Diseases, Hormonal Disorders, Inflammatory & Infectious Diseases, Metabolic Disorders, Neurological Diseases, and Oncology.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Biopharmaceuticals market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Biopharmaceuticals Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Biopharmaceuticals Market, including Abbott Laboratories, Abbvie Inc., Amgen, Inc., Biogen, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche, Ltd., Johnson & Johnson, Merck & Co., Inc., Novo Nordisk A/S, Pfizer, Inc., and Sanofi S.A..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Biopharmaceuticals Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Biopharmaceuticals Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biopharmaceuticals Market?
4. What is the competitive strategic window for opportunities in the Global Biopharmaceuticals Market?
5. What are the technology trends and regulatory frameworks in the Global Biopharmaceuticals Market?
6. What is the market share of the leading vendors in the Global Biopharmaceuticals Market?
7. What modes and strategic moves are considered suitable for entering the Global Biopharmaceuticals Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing adoption to treat chronic disorders
5.1.1.2. Growing investments for vaccine manufacturing
5.1.1.3. Rising numbers of clinical trials for biosimilars and biologics
5.1.2. Restraints
5.1.2.1. High costs of drug development
5.1.3. Opportunities
5.1.3.1. Advancements in manufacturing of biopharmaceuticals
5.1.3.2. Significant growth in number of governmental approvals
5.1.4. Challenges
5.1.4.1. Strict governmental policies
5.2. Cumulative Impact of COVID-19
6. Biopharmaceuticals Market, by Product Type
6.1. Introduction
6.2. Monoclonal Antibodies
6.3. Purified Proteins
6.4. Recombinant Growth Factors
6.5. Recombinant Hormone
6.6. Recombinant Proteins
6.7. Synthetic Immunomodulators
6.8. Vaccines
7. Biopharmaceuticals Market, by Service
7.1. Introduction
7.2. Compendial & Multi Compendial Laboratory Testing
7.3. Custom Testing / Customer Proprietary Testing
7.4. Laboratory Testing
8. Biopharmaceuticals Market, by Raw Material Type
8.1. Introduction
8.2. Active Pharmaceutical Ingredients (API)
8.3. Compendial Methods
8.4. ormulation Excipients
9. Biopharmaceuticals Market, by Application
9.1. Introduction
9.2. Autoimmune Disorders
9.3. Cardiovascular Diseases
9.4. Hormonal Disorders
9.5. Inflammatory & Infectious Diseases
9.6. Metabolic Disorders
9.7. Neurological Diseases
9.8. Oncology
10. Americas Biopharmaceuticals Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Biopharmaceuticals Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Biopharmaceuticals Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Abbott Laboratories
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Abbvie Inc.
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Amgen, Inc.
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Biogen, Inc.
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Bristol-Myers Squibb Company
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Eli Lilly and Company
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. F. Hoffmann-La Roche, Ltd.
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Johnson & Johnson
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Merck & Co., Inc.
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Novo Nordisk A/S
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Pfizer, Inc.
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Sanofi S.A.
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing